This cross-talk may be particularly relevant in hormone-dependent cancers such as breast and prostate cancers, in which inhibition of the dominant hormone receptor (i.e., AR in prostate cancer) can lead to alternative hormone receptors supporting tumor cell growth by hijacking the signaling cascade. Here, NR4A1 is linked to prostate cancer.